Effectiveness of Vitamin E as an add on with standard therapy and its effect on patients with chronic kidney disease on renal dialysis

Evaluation of Vitamin E as an add on with standard therapy and its effect on plasma Pentraxin-3 in patients with chronic kidney disease on renal dialysis A Randomized control Clinical Trail

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/08/036020

Enrollment

150

Registered

2021-08-27

Start date

Unknown

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N185- Chronic kidney disease, stage 5

Interventions

Intervention1: Vitamin-E: capsule Vitamin -E 600mg per day, per oral, post dialysis will be added for 12 weeks along with thier standard therapy Control Intervention1: Standard or usual therapy for pa

Eligibility

Inclusion criteria

Inclusion criteria: Patients of either gender, suffering from chronic kidney disease on hemodialysis at least for 3 months and age of 40 years to 70 years. CKD patients on haemodialysis who were able to understand and agree for informed written informed consent for the participation in this study. CKD patients on haemodialysis with Diabetes mellitus and hypertension as co-morbidities.

Exclusion criteria

Exclusion criteria: CKD patients on haemodialysis who were disable or immobile. CKD patients on haemodialysis with associated chronic liver disease (CLD), congestive heart failure (CHF), HIV, Active tuberculosis. CKD patients on haemodialysis with immunosuppressive therapy and clinical signs of ongoing infection. CKD patients with haemodialysis not on antioxidant therapy for last 3-6 months.

Design outcomes

Primary

Measure	Time frame
The outcome of this study will help us to understand the significance of measuring serum PTX-3 levels among CKD patients on dialysis. The present investigation will also reveal the risk of morbidity and mortality among two groups. The outcome will also determine whether the extent of tissue injury (marked by the serum concentration of PTX-3) has any significant change between two groups.Timepoint: At baseline, 4 weeks, 8 weeks and 12 weeks	—

Measure

Time frame

The outcome of this study will help us to understand the significance of measuring serum PTX-3 levels among CKD patients on dialysis. The present investigation will also reveal the risk of morbidity and mortality among two groups. The outcome will also determine whether the extent of tissue injury (marked by the serum concentration of PTX-3) has any significant change between two groups.Timepoint: At baseline, 4 weeks, 8 weeks and 12 weeks

—

Secondary

Measure	Time frame
Impact of Anti-oxidents in CKD patients on dialysis will be determined by serum pentroxin-3 levelTimepoint: At baseline, 4 weeks, 8 weeks and 12 weeks	—

Countries

India

Contacts

Public ContactJagadeesan M

SRM Medical College Hospital and Research Centre, SRMIST,

sreedhas@srmist.edu.in9444012894

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026